



WHAT IS CLAIMED IS:


- 1 1. A compound of any one of Formulae (IA), (IB), (IC), (IIA), (IIB) or
 2 (IIC):




IA




IB




IC



IIA



IIB



IIC

- 3 or a pharmaceutically acceptable salt thereof, wherein,
 4 ring vertex a is N or C(R^{2c}), ring vertex b is N or C(R^{2d}), and ring vertex e is N or C(R^{2e}),
 5 wherein no more than one of a, b and e is N;
 6 X¹ is selected from the group consisting of a bond, C₁₋₈ alkylene, C(O), C(O)-C₁₋₄ alkylene,
 7 and S(O)₂;
 8 R¹ is selected from the group consisting of
 9 a) 5- to 10-membered heteroaryl having from 1 to 4 heteroatoms as ring vertices selected
 10 from N, O and S;
 11 b) C₆₋₁₀ aryl;
 12 c) C₃₋₈ cycloalkyl;

- 14 d) 4- to 8-membered heterocycloalkyl having from 1 to 2 heteroatoms as ring vertices
15 selected from N, O and S; and
- 16 e) C₁₋₈ alkyl, C₁₋₈ alkoxy, C₁₋₈ haloalkyl, -C(O)NR^{1a}R^{1b}, and -CO₂R^{1a}; wherein R^{1a} and
17 R^{1b} are each independently selected from the group consisting of hydrogen, C₁₋₈
18 alkyl, C₆₋₁₀ aryl, and -C₁₋₆ alkylene-C₆₋₁₀ aryl;
- 19 wherein the group -X¹-R¹ is unsubstituted or substituted with 1 to 5 R^x substituents;
20 R^{2a} and R^{2e} are each independently selected from the group consisting of hydrogen, C₁₋₆
21 alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, -O-C₁₋₆ haloalkyl, -S-C₁₋₆ alkyl, -C₁₋₆ alkyl-O-C₁₋₆
22 alkyl, -C₁₋₆ alkyl-S-C₁₋₆ alkyl, CN, and halogen, and at least one of R^{2a} and R^{2e} is
23 other than hydrogen;
- 24 R^{2b}, R^{2c}, and R^{2d} are each independently selected from the group consisting of hydrogen, C₁₋₆
25 alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, -O-C₁₋₆ haloalkyl, -S-C₁₋₆ alkyl, -C₁₋₆ alkyl-O-C₁₋₆
26 alkyl, -C₁₋₆ alkyl-S-C₁₋₆ alkyl, cyano, and halogen;
- 27 each R³ is independently selected from the group consisting of hydroxyl, C₁₋₄ alkyl, C₁₋₄
28 haloalkyl and C₁₋₄ hydroxyalkyl, and optionally two R³ groups on the same carbon
29 atom are combined to form oxo (=O), and optionally two R³ groups and the carbon
30 atoms they are attached to form a 3-6 membered ring with 0-2 heteroatoms as ring
31 members selected from O, N, and S;
- 32 R⁴ is a member selected from the group consisting of: -NHP¹, -NHC(O)NHP¹, -CH₂NHP¹
33 and -CH₂NHC(O)NHP¹;
- 34 each R⁵ is independently selected from the group consisting of C₁₋₈ alkyl, C₁₋₈ alkoxy, C₁₋₈
35 haloalkyl, C₁₋₈ haloalkoxy, C₁₋₈ hydroxyalkyl, halogen, OH, CN, C(O)R^{5a} and
36 CO₂R^{5a};
- 37 R^{5*} is a member selected from the group consisting of hydrogen, C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₁₋₈
38 hydroxyalkyl, C(O)R^{5a} and CO₂R^{5a}; wherein each R^{5a} is independently selected
39 from the group consisting of hydrogen, C₁₋₄ alkyl, and C₁₋₄ haloalkyl;
- 40 R⁶ is a member selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆
41 haloalkyl, -O-C₁₋₆ haloalkyl, -S-C₁₋₆ alkyl, -C₁₋₆ alkyl-O-C₁₋₆ alkyl, -C₁₋₆ alkyl-S-C₁₋₆
42 alkyl, cyano, and halogen;
- 43 R⁷ is P¹; and
- 44 R⁸ is -CH₂OP¹;

45 each P¹ is a prodrug component;
46 each R^x is independently selected from the group consisting of halogen, CN, C₁₋₄ alkyl, C₁₋₄
47 alkoxy, C₁₋₄ haloalkyl, C₁₋₄ haloalkoxy, C₁₋₄ hydroxyalkyl, C₂₋₄ alkenyl, C₃₋₆
48 cycloalkyl, CO₂-C₁₋₄ alkyl, and CONH₂;
49 the subscript m is 0, 1, 2, 3 or 4; and
50 the subscript n is 0, 1, 2 or 3.

1 **2.** The compound of claim **1**, or a pharmaceutically acceptable salt thereof,
2 having Formula **IA**.

1 **3.** The compound of claim **1**, or a pharmaceutically acceptable salt thereof,
2 having Formula **IB**.


1 **4.** The compound of claim **1**, or a pharmaceutically acceptable salt thereof,
2 having Formula **IC**.

1 **5.** The compound of claim **1**, or a pharmaceutically acceptable salt thereof,
2 having Formula **IIA**.

1 **6.** The compound of claim **1**, or a pharmaceutically acceptable salt thereof,
2 having Formula **IIB**.


1 **7.** The compound of claim **1**, or a pharmaceutically acceptable salt thereof,
2 having Formula **IIC**.

1 **8.** The compound of any one of claims **1** to **7**, or a pharmaceutically
2 acceptable salt thereof, wherein P¹ is selected from the group consisting of:



wherein each R^9 is independently selected from the group consisting of H and C_{1-3} alkyl;
and
each R^{10} is independently selected from the group consisting of H, C_{1-3} alkyl, phenyl, and
benzyl.

9. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein P^1 is selected from the group consisting of:



wherein
each R^y is independently selected from the group consisting of
 $-\text{OP}(\text{O})(\text{OR}^{y1})_2$, $-\text{OC}(\text{O})\text{CH}_2\text{N}(\text{R}^{y2})_2$, $-\text{N}(\text{R}^{y2})_2$, and piperazine;
each R^{y1} is independently selected from the group consisting of H, C_{1-3} alkyl, and benzyl;
each R^{y2} is independently H or C_{1-3} alkyl; and
each phenyl ring bearing an R^y or $-\text{CH}_2\text{R}^y$ substituent is further substituted with from 0 to
3 members independently selected from the group consisting of nitro, halogen,


12 CN, CF₃, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl, C₁₋₄ haloalkoxy, and C₁₋₄
 13 hydroxyalkyl.

1 **10.** The compound of any one of claims 1 to 7, or a pharmaceutically
 2 acceptable salt thereof, wherein P¹ is selected from the group consisting of -CH₂OH,
 3 -P(O)(OR¹⁰)₂, and -CH₂-O-P(O)(OR¹⁰)₂, wherein each R¹⁰ is independently selected from the
 4 group consisting of H, C₁₋₃ alkyl, phenyl, and benzyl.

1 **11.** The compound of any one of claims 1 to 7, or a pharmaceutically
 2 acceptable salt thereof, wherein P¹ is selected from the group consisting of an amino acid, a
 3 dipeptide, and a tripeptide.

1 **12.** The compound of claim 12, where said amino acid, dipeptide, or tripeptide
 2 moieties are independently selected from the group consisting of glycine, alanine, valine,
 3 leucine, isoleucine, lysine, cysteine, aspartate, glutamate, histidine, and phenylalanine, wherein
 4 the N atom of each amino acid unit may be methylated or acylated.

1 **13.** The compound of any one of claims 1 to 7, or a pharmaceutically
 2 acceptable salt thereof, wherein P¹ is selected from the group consisting of:



1 **14.** The compound of any one of claims 1 to 7, or a pharmaceutically
 2 acceptable salt thereof, wherein X¹ is C(O)-C₁₋₄ alkylene or S(O)₂.

1 **15.** The compound of any one of claims 1 to 14, or a pharmaceutically
 2 acceptable salt thereof, wherein R¹ is a 5- to 10-membered heteroaryl having from 1 to 4
 3 heteroatoms as ring vertices selected from N, O and S; and wherein the group -X¹-R¹ is
 4 optionally substituted with 1 to 4 R^x substituents.

1 **16.** The compound of claim **15**, wherein R^1 is selected from the group
2 consisting of pyrazolyl, pyridyl, pyrimidinyl, imidazolyl, thiazolyl, thiadiazolyl and pyrazinyl;
3 and wherein the group $-X^1-R^1$ is optionally substituted with 1 to 4 R^x substituents.

1 **17.** The compound of any one of claims **1** to **14**, or a pharmaceutically
2 acceptable salt thereof, wherein R^1 is C_{6-10} aryl; and wherein the group $-X^1-R^1$ is optionally
3 substituted with 1 to 4 R^x substituents.

1 **18.** The compound of claim **17**, wherein R^1 is phenyl; and wherein the group $-$
2 X^1-R^1 is optionally substituted with 1 to 4 R^x substituents.

1 **19.** The compound of any one of claims **1** to **14**, or a pharmaceutically
2 acceptable salt thereof, wherein R^1 is C_{3-8} cycloalkyl; and wherein the group $-X^1-R^1$ is optionally
3 substituted with 1 to 4 R^x substituents.

1 **20.** The compound of claim **19**, wherein R^1 is selected from the group
2 consisting of cyclobutyl, cyclopentyl and cyclohexyl; and wherein the group $-X^1-R^1$ is optionally
3 substituted with 1 to 4 R^x substituents.

1 **21.** The compound of any one of claims **1** to **14**, or a pharmaceutically
2 acceptable salt thereof, wherein R^1 is a 4- to 8-membered heterocycloalkyl having from 1 to 2
3 heteroatoms as ring vertices selected from N, O and S; and wherein the group $-X^1-R^1$ is
4 optionally substituted with 1 to 4 R^x substituents.

1 **22.** The compound of claim **21**, wherein R^1 is selected from the group
2 consisting of oxetanyl, tetrahydrofuranyl, tetrahydropyranyl and morpholinyl; and wherein the
3 group $-X^1-R^1$ is optionally substituted with 1 to 4 R^x substituents.

1 **23.** The compound of any one of claims **1** to **14**, or a pharmaceutically
2 acceptable salt thereof, wherein R^1 is selected from the group consisting of C_{1-8} alkyl, C_{1-8}
3 alkoxy, C_{1-8} haloalkyl, $-C(O)NR^{1a}R^{1b}$, and $-CO_2R^{1a}$; wherein R^{1a} and R^{1b} are each independently
4 selected from the group consisting of hydrogen, C_{1-8} alkyl, C_{6-10} aryl, and $-C_{1-6}$ alkylene- C_{6-10}
5 aryl; and wherein the group $-X^1-R^1$ is optionally substituted with 1 to 4 R^x substituents.

1 **24.** The compound of any one of claims **1** to **14**, or a pharmaceutically
2 acceptable salt thereof, wherein R^1 is selected from the group consisting of phenyl, pyridyl,
3 pyrimidinyl, and pyrazinyl; and wherein the group $-X^1-R^1$ is optionally substituted with 1 to 4 R^x
4 substituents.

1 **25.** The compound of any one of claims **1** to **24**, or a pharmaceutically
2 acceptable salt thereof, wherein ring vertices a and b are CH; R^{2b} is H; ring vertex e is $C(R^{2e})$,
3 and R^{2a} and R^{2e} are independently selected from the group consisting of C_{1-6} alkyl, C_{1-6} alkoxy,
4 C_{1-6} haloalkyl, $-O-C_{1-6}$ haloalkyl, $-S-C_{1-6}$ alkyl, $-C_{1-6}$ alkyl- $O-C_{1-6}$ alkyl, $-C_{1-6}$ alkyl- $S-C_{1-6}$ alkyl,
5 CN, and halogen.

1 **26.** The compound of any one of claims **1** to **24**, or a pharmaceutically
2 acceptable salt thereof, wherein ring vertices a and b are CH; R^{2b} is H; ring vertex e is $C(R^{2e})$,
3 and R^{2a} and R^{2e} are independently selected from the group consisting of C_{1-6} alkyl, C_{1-6} alkoxy
4 and halogen.

1 **27.** The compound of any one of claims **1** to **26**, or a pharmaceutically
2 acceptable salt thereof, wherein n is 0, 1 or 2 and each R^5 , when present, is selected from the
3 group consisting of F, Cl, CN, C_{1-4} alkyl and C_{1-4} alkoxy.

1 **28.** The compound of any one of claims **1** to **26**, or a pharmaceutically
2 acceptable salt thereof, wherein n is 0, 1 or 2 and each R^5 , when present, is selected from the
3 group consisting of F, Cl, CN, CH_3 and OCH_3 .


1 **29.** The compound of any one of claims **1** to **26**, or a pharmaceutically
2 acceptable salt thereof, wherein m is 0, 1 or 2 and each R^3 , when present, is C_{1-4} alkyl.

1 **30.** The compound of claim **1**, or a pharmaceutically acceptable salt thereof,
2 wherein R^1 is selected from the group consisting of phenyl or pyridyl, wherein the group $-X^1-R^1$
3 is optionally substituted with 1 to 4 R^x substituents; ring vertices a and b are CH; R^{2b} is H; ring
4 vertex e is $C(R^{2e})$, and R^{2a} and R^{2e} are independently selected from the group consisting of C_{1-6}
5 alkyl, C_{1-6} alkoxy and halogen; m is 0, 1 or 2 and each R^3 , when present, is CH_3 ; R^4 , when
6 present, is selected from the group consisting of


7 ;

8 n is 0, 1 or 2 and each R⁵, when present, is selected from the group consisting of F, Cl, CN, CH₃
 9 and OCH₃.

1 **31.** The compound of claim 1, or a pharmaceutically acceptable salt thereof,
 2 wherein R¹ is selected from the group consisting of



1 **32.** The compound of claim 1, or a pharmaceutically acceptable salt thereof,
 2 wherein -X¹-R¹ is selected from the group consisting of:




3

1

2

33. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R¹ is selected from the group consisting of:




3

1

2

3

34. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R¹ is selected from the group consisting of:




4

1


2


35. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R¹ is selected from the group consisting of:



3

1 **36.** The compound of any one of claims **1** to **35**, or a pharmaceutically

2 acceptable salt thereof, wherein  is selected from the group consisting of



1 **37.** The compound of any one of claims **1** to **36**, or a pharmaceutically
2 acceptable salt thereof, wherein n is 0.

1 **38.** The compound of any one of claims **1** to **36**, or a pharmaceutically
2 acceptable salt thereof, wherein n is 2 and the two R³ groups are on the same carbon atom and
3 are combined to form oxo (=O).

1 **39.** A pharmaceutical composition comprising a compound of any one of
2 claims **1** to **38** or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable
3 carrier.

1 **40.** The pharmaceutical composition of claim **39**, formulated for oral,
2 intravenous, transdermal or subcutaneous administration.

1 **41.** The pharmaceutical composition of claim **39** or **40**, further comprising one
2 or more additional therapeutic agents.

1 **42.** The pharmaceutical composition of claim **41**, wherein the one or more
2 additional therapeutic agent is selected from the group consisting of corticosteroids, steroids,
3 immunosuppressants, Immunoglobulin G agonists, Dipeptidyl peptidase IV inhibitors,
4 Lymphocyte function antigen-3 receptor antagonists, Interleukin-2 ligands, Interleukin-1 beta

5 ligand inhibitors, IL-2 receptor alpha subunit inhibitors, HGF gene stimulators, IL-6 antagonists,
6 IL-5 antagonists, Alpha 1 antitrypsin stimulators, Cannabinoid receptor antagonists, Histone
7 deacetylase inhibitors, AKT protein kinase inhibitors, CD20 inhibitors, Abl tyrosine kinase
8 inhibitors, JAK tyrosine kinase inhibitors, TNF alpha ligand inhibitors, Hemoglobin modulators,
9 TNF antagonists, proteasome inhibitors, CD3 modulators, Hsp 70 family inhibitors,
10 Immunoglobulin agonists, CD30 antagonists, tubulin antagonists, Sphingosine-1-phosphate
11 receptor-1 agonists, connective tissue growth factor ligand inhibitors, caspase inhibitors,
12 adrenocorticotrophic hormone ligands, Btk tyrosine kinase inhibitors, Complement C1s
13 subcomponent inhibitors, Erythropoietin receptor agonists, B-lymphocyte stimulator ligand
14 inhibitors, Cyclin-dependent kinase-2 inhibitors, P-selectin glycoprotein ligand-1 stimulators,
15 mTOR inhibitors, Elongation factor 2 inhibitors, Cell adhesion molecule inhibitors, Factor XIII
16 agonists, Calcineurin inhibitors, Immunoglobulin G1 agonists, Inosine monophosphate
17 dehydrogenase inhibitors, Complement C1s subcomponent inhibitors, Thymidine kinase
18 modulators, Cytotoxic T-lymphocyte protein-4 modulators, Angiotensin II receptor antagonists,
19 Angiotensin II receptor modulators, TNF superfamily receptor 12A antagonists, CD52
20 antagonists, Adenosine deaminase inhibitors, T-cell differentiation antigen CD6 inhibitors, FGF-
21 7 ligands, dihydroorotate dehydrogenase inhibitors, Syk tyrosine kinase inhibitors, Interferon
22 type I receptor antagonists, Interferon alpha ligand inhibitors, Macrophage migration inhibitory
23 factor inhibitors, Integrin alpha-V/beta-6 antagonists, Cysteine protease stimulators, p38 MAP
24 kinase inhibitors, TP53 gene inhibitors, Shiga like toxin I inhibitors, Fucosyltransferase 6
25 stimulators, Interleukin 22 ligands, IRS1 gene inhibitors, Protein kinase C stimulators, Protein
26 kinase C alpha inhibitors, CD74 antagonists, Immunoglobulin gamma Fc receptor IIB
27 antagonists, T-cell antigen CD7 inhibitors, CD95 antagonists, N acetylmannosamine kinase
28 stimulators, Cardiotrophin-1 ligands, Leukocyte elastase inhibitors, CD40 ligand receptor
29 antagonists, CD40 ligand modulators, IL-17 antagonists, TLR-2 antagonists, Mannan-binding
30 lectin serine protease-2 (MASP-2) inhibitors, Factor B inhibitors, Factor D inhibitors, C3aR
31 modulators, C5aR2 modulators, T cell receptor antagonists, PD-1 inhibitors, PD-L1 inhibitors,
32 TIGIT inhibitors, TIM-3 inhibitors, LAG-3 inhibitors, VISTA inhibitors, STING agonists, IDO
33 inhibitors, adenosine receptor modulators, CD39 inhibitors, CD73 inhibitors, antagonists of the
34 chemokine receptors, especially CXCR1, CXCR2, CXCR3, CXCR4, CXCR7, CCR1, CCR2,
35 CCR3, CCR4, CCR5, CCR7, CCR9, CX3CR1 and CXCR6, and combinations thereof.

1 **43.** The pharmaceutical composition of any one of claims **41** or **42**, wherein
2 the one or more additional therapeutic agent is selected from the group consisting of
3 obinutuzumab, rituximab, ocrelizumab, cyclophosphamide, prednisone, hydrocortisone,
4 hydrocortisone acetate, cortisone acetate, tixocortol pivalate, prednisolone, methylprednisolone,
5 triamcinolone acetonide, triamcinolone alcohol, mometasone, amcinonide, budesonide, desonide,
6 fluocinonide, fluocinolone acetonide, halcinonide, betamethasone, betamethasone sodium
7 phosphate, dexamethasone, dexamethasone sodium phosphate, fluocortolone, hydrocortisone-17-
8 valerate, halometasone, alclometasone dipropionate, beclomethasone, betamethasone valerate,
9 betamethasone dipropionate, prednicarbate, clobetasone-17-butyrate, clobetasol-17-propionate,
10 fluocortolone caproate, fluocortolone pivalate, fluprednidene acetate, hydrocortisone-17-
11 butyrate, hydrocortisone-17-aceponate, hydrocortisone-17-buteprate, ciclesonide and
12 prednicarbate, GB-0998, immuglo, begelomab, alefacept, aldesleukin, gevokizumab,
13 daclizumab, basiliximab, inolimomab, beperminogene perplasmid, sirukumab, tocilizumab,
14 clazakizumab, mepolizumab, fingolimod, panobinostat, tricitiribine, nilotinib, imatinib,
15 tofacitinib, momelotinib, peficitinib, itacitinib, infliximab, PEG-bHb-CO, etanercept, ixazomib,
16 bortezomib, muromonab, otelixizumab, gusperimus, brentuximab vedotin, Ponesimod, KRP-203,
17 FG-3019, emricasan, corticotropin, ibrutinib, cinryze, conestat, methoxy polyethylene glycol-
18 epoetin beta, belimumab, blisibimod, atacicept, seliciclib, neihulizumab, everolimus, sirolimus,
19 denileukin diftitox, LMB-2, natalizumab, catridecacog, ciclosporin, tacrolimus, voclosporin,
20 voclosporin, canakinumab, mycophenolate, mizoribine, CE-1145, TK-DLI, abatacept,
21 belatacept, olmesartan medoxomil, sparsentan, TXA-127, BIIB-023, alemtuzumab, pentostatin,
22 itolizumab, palifermin, leflunomide, PRO-140, cenicriviroc, fostamatinib, anifrolumab,
23 sifalimumab, BAX-069, BG-00011, losmapimod, QPI-1002, ShigamAbs, TZ-101, F-652,
24 reparixin, ladarixin, PTX-9908, aganirsen, APH-703, sotrastaurin, sotrastaurin, milatuzumab,
25 SM-101, T-Guard, APG-101, DEX-M74, cardiotrophin-1, tiprelestat, ASKP-1240, BMS-
26 986004, HPH-116, KD-025, OPN-305, TOL-101, defibrotide, pomalidomide, Thymoglobulin,
27 laquinimod, remestemcel-L, Equine antithymocyte immunoglobulin, Stempeucel, LIV-Gamma,
28 Octagam 10%, t2c-001, 99mTc-sestamibi, Clairyg, Prosorba, pomalidomide, laquinimod,
29 teplizumab, FCRx, solnatide, foralumab, ATIR-101, BPX-501, ACP-01, ALLO-ASC-DFU,
30 irbesartan + propagermanium, ApoCell, cannabidiol, RGI-2001, saratin, anti-CD3 bivalent
31 antibody-diphtheria toxin conjugate, NOX-100, LT-1951, OMS721, ALN-CC5, ACH-4471,

32 AMY-101, Acthar gel, and CD4+CD25+ regulatory T-cells, MEDI7814, P32, P59,
33 pembrolizumab, nivolumab, atezolizumab, avelumab, durvalumab, CCX354, CCX721,
34 CCX9588, CCX140, CCX872, CCX598, CCX6239, CCX587, CCX624, CCX282, CCX025,
35 CCX507, CCX430, CCX765, CCX758, CCX771, CCX662, CCX650, and combinations
36 thereof..

1 **44.** A method of treating a human suffering from or susceptible to a disease or
2 disorder involving pathologic activation of C5a receptors, comprising administering to the
3 mammal a therapeutically effective amount of a compound of any one of claims 1 to 16 or a
4 pharmaceutical composition of any one of claims **39** to **43**.

1 **45.** The method of claim **44**, wherein the disease or disorder is an
2 inflammatory disease or disorder, an autoimmune disease, or an oncologic disease or disorder.

1 **46.** The method of claim **44**, wherein the disease or disorder is a
2 cardiovascular or cerebrovascular disorder.

1 **47.** The method of claim **44**, wherein the disease or disorder is selected from
2 the group consisting of neutropenia, neutrophilia, Wegener's granulomatosis, microscopic
3 polyangiitis, C3-glomerulopathy, C3-glomerulonephritis, dense deposit disease,
4 membranoproliferative glomerulonephritis, Kawasaki disease, sepsis, septic shock, Hemolytic
5 uremic syndrome, atypical hemolytic uremic syndrome (aHUS), Alzheimer's disease, multiple
6 sclerosis, stroke, inflammatory bowel disease, chronic obstructive pulmonary disorder,
7 inflammation associated with burns, lung injury, osteoarthritis, atopic dermatitis, chronic
8 urticaria, ischemia-reperfusion injury, acute respiratory distress syndrome, systemic
9 inflammatory response syndrome, multiple organ dysfunction syndrome, Uveitis, tissue graft
10 rejection, hyperacute rejection of transplanted organs, myocardial infarction, coronary
11 thrombosis, vascular occlusion, post-surgical vascular reocclusion, arteriosclerosis, polypoidal
12 choroidal vasculopathy, traumatic central nervous system injury, ischemic heart disease,
13 rheumatoid arthritis, systemic lupus erythematosus, Guillain- Barre syndrome, pancreatitis, lupus
14 nephritis, lupus glomerulonephritis, psoriasis, Crohn's disease, vasculitis, ANCA vasculitis,
15 irritable bowel syndrome, dermatomyositis, multiple sclerosis, bronchial asthma, pemphigus,
16 pemphigoid, scleroderma, myasthenia gravis, autoimmune hemolytic and thrombocytopenic

17 states, Goodpasture's syndrome, immuno vasculitis, Graft versus host disease, Paroxysmal
18 nocturnal hemoglobinuria, Sjogrens syndrome, insulin-dependent diabetes, mellitus, lupus
19 nephropathy, Heyman nephritis, membranous nephritis, glomerulonephritis, IGA nephropathy,
20 Membranoproliferative glomerulonephritis, Antiphospholipid syndrome, Age related macular
21 degeneration; Dry age related macular degeneration, Wet age related macular degeneration,
22 Motor neurone disease, contact sensitivity responses, hidradenitis suppurativa, and inflammation
23 resulting from contact of blood with artificial surfaces.

1 **48.** The method of claim **44**, wherein the disease or disorder is selected from
2 the group consisting of neutropenia, neutrophilia, Wegener's granulomatosis, microscopic
3 polyangiitis, C3-glomerulopathy, C3-glomerulonephritis, dense deposit disease,
4 membranoproliferative glomerulonephritis, Kawasaki disease, Hemolytic uremic syndrome,
5 atypical hemolytic uremic syndrome (aHUS), tissue graft rejection, hyperacute rejection of
6 transplanted organs, rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, lupus
7 glomerulonephritis, vasculitis, ANCA vasculitis, autoimmune hemolytic and thrombocytopenic
8 states, immuno vasculitis, Graft versus host disease, lupus nephropathy, Heyman nephritis,
9 membranous nephritis, glomerulonephritis, IGA nephropathy, hidradenitis suppurativa, and
10 Membranoproliferative glomerulonephritis.

1 **49.** The method of claim **44**, wherein the disease or disorder is selected from
2 the group consisting of melanoma, lung cancer, lymphoma, sarcoma, carcinoma, fibrosarcoma,
3 liposarcoma, chondrosarcoma, osteogenic sarcoma, angiosarcoma, lymphangiosarcoma,
4 synovioma, mesothelioma, meningioma, leukemia, lymphoma, leiomyosarcoma,
5 rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, papillary
6 carcinoma, cystadenocarcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatocellular
7 carcinoma, transitional cell carcinoma, choriocarcinoma, seminoma, embryonal carcinoma,
8 wilm's tumor, pleomorphic adenoma, liver cell papilloma, renal tubular adenoma, cystadenoma,
9 papilloma, adenoma, leiomyoma, rhabdomyoma, hemangioma, lymphangioma, osteoma,
10 chondroma, lipoma and fibroma.

1 **50.** The method of any one of claims **44** to **49**, further comprising
2 administering to the human a therapeutically effective amount of one or more additional
3 therapeutic agents.

1 **51.** The method of claim **50**, wherein the one or more additional therapeutic
2 agents is selected from the group consisting of corticosteroids, steroids, immunosuppressants,
3 Immunoglobulin G agonists, Dipeptidyl peptidase IV inhibitors, Lymphocyte function antigen-3
4 receptor antagonists, Interleukin-2 ligands, Interleukin-1 beta ligand inhibitors, IL-2 receptor
5 alpha subunit inhibitors, HGF gene stimulators, IL-6 antagonists, IL-5 antagonists, Alpha 1
6 antitrypsin stimulators, Cannabinoid receptor antagonists, Histone deacetylase inhibitors, AKT
7 protein kinase inhibitors, CD20 inhibitors, Abl tyrosine kinase inhibitors, JAK tyrosine kinase
8 inhibitors, TNF alpha ligand inhibitors, Hemoglobin modulators, TNF antagonists, proteasome
9 inhibitors, CD3 modulators, Hsp 70 family inhibitors, Immunoglobulin agonists, CD30
10 antagonists, tubulin antagonists, Sphingosine-1-phosphate receptor-1 agonists, connective tissue
11 growth factor ligand inhibitors, caspase inhibitors, adrenocorticotrophic hormone ligands, Btk
12 tyrosine kinase inhibitors, Complement C1s subcomponent inhibitors, Erythropoietin receptor
13 agonists, B-lymphocyte stimulator ligand inhibitors, Cyclin-dependent kinase-2 inhibitors, P-
14 selectin glycoprotein ligand-1 stimulators, mTOR inhibitors, Elongation factor 2 inhibitors, Cell
15 adhesion molecule inhibitors, Factor XIII agonists, Calcineurin inhibitors, Immunoglobulin G1
16 agonists, Inosine monophosphate dehydrogenase inhibitors, Complement C1s subcomponent
17 inhibitors, Thymidine kinase modulators, Cytotoxic T-lymphocyte protein-4 modulators,
18 Angiotensin II receptor antagonists, Angiotensin II receptor modulators, TNF superfamily
19 receptor 12A antagonists, CD52 antagonists, Adenosine deaminase inhibitors, T-cell
20 differentiation antigen CD6 inhibitors, FGF-7 ligands, dihydroorotate dehydrogenase inhibitors,
21 Syk tyrosine kinase inhibitors, Interferon type I receptor antagonists, Interferon alpha ligand
22 inhibitors, Macrophage migration inhibitory factor inhibitors, Integrin alpha-V/beta-6
23 antagonists, Cysteine protease stimulators, p38 MAP kinase inhibitors, TP53 gene inhibitors,
24 Shiga like toxin I inhibitors, Fucosyltransferase 6 stimulators, Interleukin 22 ligands, IRS1 gene
25 inhibitors, Protein kinase C stimulators, Protein kinase C alpha inhibitors, CD74 antagonists,
26 Immunoglobulin gamma Fc receptor IIB antagonists, T-cell antigen CD7 inhibitors, CD95
27 antagonists, N acetylmannosamine kinase stimulators, Cardiotrophin-1 ligands, Leukocyte

28 elastase inhibitors, CD40 ligand receptor antagonists, CD40 ligand modulators, IL-17
29 antagonists, TLR-2 antagonists, Mannan-binding lectin serine protease-2 (MASP-2) inhibitors,
30 Factor B inhibitors, Factor D inhibitors, C3aR modulators, C5aR2 modulators, T cell receptor
31 antagonists, PD-1 inhibitors, PD-L1 inhibitors, TIGIT inhibitors, TIM-3 inhibitors, LAG-3
32 inhibitors, VISTA inhibitors, STING agonists, IDO inhibitors, adenosine receptor modulators,
33 CD39 inhibitors, CD73 inhibitors, antagonists of the chemokine receptors, especially CXCR1,
34 CXCR2, CXCR3, CXCR4, CXCR7, CCR1, CCR2, CCR3, CCR4, CCR5, CCR7, CCR9,
35 CX3CR1 and CXCR6, and combinations thereof.

1 **52.** The method of claim **50** or **51**, wherein the one or more additional
2 therapeutic agent is selected from the group consisting of obinutuzumab, rituximab, ocrelizumab,
3 cyclophosphamide, prednisone, hydrocortisone, hydrocortisone acetate, cortisone acetate,
4 tixocortol pivalate, prednisolone, methylprednisolone, triamcinolone acetonide, triamcinolone
5 alcohol, mometasone, amcinonide, budesonide, desonide, fluocinonide, fluocinolone acetonide,
6 halcinonide, betamethasone, betamethasone sodium phosphate, dexamethasone, dexamethasone
7 sodium phosphate, fluocortolone, hydrocortisone-17-valerate, halometasone, alclometasone
8 dipropionate, beclomethasone, betamethasone valerate, betamethasone dipropionate,
9 prednicarbate, clobetasone-17-butyrate, clobetasol-17-propionate, fluocortolone caproate,
10 fluocortolone pivalate, fluprednidene acetate, hydrocortisone-17-butyrate, hydrocortisone-17-
11 aceponate, hydrocortisone-17-buteprate, ciclesonide and prednicarbate, GB-0998, immuglo,
12 begelomab, alefacept, aldesleukin, gevokizumab, daclizumab, basiliximab, inolimomab,
13 beperminogene perplasmid, sirukumab, tocilizumab, clazakizumab, mepolizumab, fingolimod,
14 panobinostat, triciribine, nilotinib, imatinib, tofacitinib, momelotinib, peficitinib, itacitinib,
15 infliximab, PEG-bHb-CO, etanercept, ixazomib, bortezomib, muromonab, otelixizumab,
16 gusperimus, brentuximab vedotin, Ponesimod, KRP-203, FG-3019, emricasan, corticotropin,
17 ibrutinib, cinryze, conestat, methoxy polyethylene glycol-epoetin beta, belimumab, blisibimod,
18 atacicept, seliciclib, neihulizumab, everolimus, sirolimus, denileukin diftitox, LMB-2,
19 natalizumab, catridecacog, ciclosporin, tacrolimus, voclosporin, voclosporin, canakinumab,
20 mycophenolate, mizoribine, CE-1145, TK-DLI, abatacept, belatacept, olmesartan medoxomil,
21 sparsentan, TXA-127, BIIB-023, alemtuzumab, pentostatin, itolizumab, palifermin, leflunomide,
22 PRO-140, cenicriviroc, fostamatinib, anifrolumab, sifalimumab, BAX-069, BG-00011,
23 losmapimod, QPI-1002, ShigamAbs, TZ-101, F-652, reparixin, ladarixin, PTX-9908, aganirsen,

24 APH-703, sotrastaurin, sotrastaurin, milatuzumab, SM-101, T-Guard, APG-101, DEX-M74,
25 cardiotrophin-1, tiprelestat, ASKP-1240, BMS-986004, HPH-116, KD-025, OPN-305, TOL-101,
26 defibrotide, pomalidomide, Thymoglobulin, laquinimod, remestemcel-L, Equine antithymocyte
27 immunoglobulin, Stempeucel, LIV-Gamma, Octagam 10%, t2c-001, 99mTc-sestamibi, Clairyg,
28 Prosorba, pomalidomide, laquinimod, teplizumab, FCRx, solnatide, foralumab, ATIR-101, BPX-
29 501, ACP-01, ALLO-ASC-DFU, irbesartan + propagermanium, ApoCell, cannabidiol, RGI-
30 2001, saratin, anti-CD3 bivalent antibody-diphtheria toxin conjugate, NOX-100, LT-1951,
31 OMS721, ALN-CC5, ACH-4471, AMY-101, Acthar gel, and CD4+CD25+ regulatory T-cells,
32 MEDI7814, P32, P59, pembrolizumab, nivolumab, atezolizumab, avelumab, durvalumab,
33 CCX354, CCX721, CCX9588, CCX140, CCX872, CCX598, CCX6239, CCX587, CCX624,
34 CCX282, CCX025, CCX507, CCX430, CCX765, CCX758, CCX771, CCX662, CCX650, and
35 combinations thereof.